North American deep brain stimulators market is expected to grow at a CAGR of around 7% during the forecast period. Deep Brain Stimulation is a device used for the treatment of neurological disorders such as Parkinson’s, Alzheimer’s and other psychiatric disorders such as dystonia, epilepsy, essential tremor, obsessive-compulsive disorder. It involves device implantation, referred to a neurostimulator. The neurostimulator works by transmitting electrical impulses through implanted electrodes, to particular targets in the brain. This, in turn, enables the treatment of neurological conditions. It is a minimally invasive procedure.
According to the Parkinson’s Foundation, every year, nearly 60,000 Americans are diagnosed with Parkinson’s disease. Moreover, over 10 million people are living with Parkinson’s globally. The possibility of having Parkinson’s among men is 1.5 times more compared to women. The incidences of Parkinson’s disease rise with the age, however, an estimated 4% of people suffering from the disease are diagnosed earlier age 50. DBS enables for the treatment of Parkinson’s symptoms such as trouble walking, stiffness and tremors. It can also be used for the treatment of side effects associated with Parkinson’s medicines. Hence, such a rise in the prevalence of Parkinson’s disease is primarily boosting the demand for deep brain stimulators devices.
Few players operating in the North American deep brain stimulators market include Medtronic PLC, Abbott Laboratories Inc., Boston Scientific Corp., LivaNova PLC, Cochlear, Ltd., Sonova Holding AG, Nevro Corp., ElectroCore LLC, and BioElectronics Corp. The market players adopt various strategies to expand their market share. For instance, in February 2019, Medtronic PLC launched deep brain stimulation for medically refractory epilepsy. The product was launched after pre-market approval from the US FDA for epilepsy as an adjunctive treatment for reducing the frequency of partial-onset seizures in individuals over 18 years of age. The US FDA approved it, based on the results from the Stimulation of the anterior nucleus of the thalamus in epilepsy trial.
Research Methodology
The market study of the North American deep brain stimulators market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include
The report is intended for medical device manufacturing companies, distributors and suppliers, and other related companies for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
The Report Covers
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. North American Deep Brain Stimulators Market by Product
5.1.1. Single Channel
5.1.2. Dual Channel
5.2. North American Deep Brain Stimulators Market by Application
5.2.1. Parkinson’s Disease
5.2.2. Depression
5.2.3. Others
5.3. North American Deep Brain Stimulators Market by End-User
5.3.1. Hospitals and Clinics
5.3.2. Research Institutes
6. Regional Analysis
6.1. United States
6.2. Canada
7. Company Profiles
7.1. Abbott Laboratories (St. Jude Medical)
7.2. Boston Scientific Corp.
7.3. Cyberonics, Inc.
7.4. Functional Neuromodulation Ltd.
7.5. Medtronic Plc
7.6. Neuronetics Inc.
7.7. NeuroPace Inc.
7.8. Neurosigma
7.9. Neurosigma Inc.
7.10. Nevro Corp.
7.11. Synapse Biomedical, Inc.
1. NORTH AMERICAN DEEP BRAIN STIMULATORS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2018-2025 ($ MILLION)
2. NORTH AMERICAN DEEP BRAIN STIMULATORS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2018-2025 ($ MILLION)
3. NORTH AMERICAN DEEP BRAIN STIMULATORS MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
4. NORTH AMERICAN DEEP BRAIN STIMULATORS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
1. NORTH AMERICAN DEEP BRAIN STIMULATORS MARKET SHARE BY PRODUCT, 2018 VS 2025 (%)
2. NORTH AMERICAN DEEP BRAIN STIMULATORS MARKET SHARE BY APPLICATION, 2018 VS 2025 (%)
3. NORTH AMERICAN DEEP BRAIN STIMULATORS MARKET SHARE BY END-USER, 2018 VS 2025 (%)
4. NORTH AMERICAN DEEP BRAIN STIMULATORS MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
5. US DEEP BRAIN STIMULATORS MARKET SIZE, 2018-2025 ($ MILLION)
6. CANADA DEEP BRAIN STIMULATORS MARKET SIZE, 2018-2025 ($ MILLION)